The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Data presented this weekend at the American College of Rheumatology’s annual meeting indicated that rheumatoid arthritis patients who adhered to a prescription drug regimen had better medical outcomes and lower medical costs.
Every 70 seconds, someone develops Alzheimer’s disease. This startling figure from the Alzheimer’s Association underlines the desperate need for new tools to diagnose and treat this debilitating illness.
Copyright © 2025 | WordPress Theme by MH Themes